Exploring the influencing factors of non-insulin drug prescriptions in discharged patients with type 1 diabetes

被引:0
作者
Cheng, Yikang [1 ,2 ]
Li, Haizhen [3 ]
Liu, Xin [4 ]
Jin, Xiaolong [2 ]
Han, Junming [2 ]
Du, Jing [5 ,6 ]
Xu, Chao [2 ,6 ]
机构
[1] Zunyi Med Univ, Clin Inst 1, Zunyi, Peoples R China
[2] Shandong First Med Univ, Shandong Prov Hosp Affiliated, Dept Endocrinol, Jinan, Peoples R China
[3] Dongying City Dist People Hosp, Dept Endocrinol, Dongying, Shandong, Peoples R China
[4] Dongying Peoples Hosp, Dept Endocrinol & Metab, Dongying, Peoples R China
[5] Inner Mongolia Univ Sci & Technol, Affiliated Hosp 1, Baotou Med Coll, Dept Endocrinol, Baotou, Peoples R China
[6] Shandong Univ, Shandong Prov Hosp, Dept Endocrinol, Jinan, Peoples R China
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
基金
国家重点研发计划;
关键词
type; 1; diabetes; factor; insulin; prescriptions; therapy; CARDIOVASCULAR-DISEASE; RISK-FACTORS; GLYCEMIC VARIABILITY; DOUBLE-BLIND; COMPLICATIONS; HYPOGLYCEMIA; LIRAGLUTIDE; OVERWEIGHT; METFORMIN; EFFICACY;
D O I
10.3389/fendo.2024.1381248
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The aim of this study was to evaluate the admission indicators and characteristics of individuals diagnosed with type 1 diabetes (T1D) to ascertain potential impact on the choice of glucose control therapy after discharge.Methods A total of 398 eligible T1D patients were selected. We conducted multivariable logistic regression analysis to determine the independent influence of predictors on the selection of glucose control therapy after discharge. To explore the influencing factors of different subgroups, we additionally performed subgroup analyses based on gender and age.Results Our study revealed that body mass index (BMI) was noteworthy influence factor for prescription of insulin and non-insulin antidiabetic drug (NIAD prescription) in T1D patients of general population [OR = 1.109 (1.033-1.195), p = 0.006], male [OR = 1.166 (1.040-1.318), p = 0.011] and individuals below the age of 30 years [OR = 1.146 (1.020-1.301), p = 0.028]. Diastolic blood pressure (DBP) was a protective factor for NIAD prescription in the general population [OR = 0.971 (0.949-0.992), p = 0.008] and women [OR = 0.955 (0.923-0.988), p = 0.008]. The other risk factor of NIAD prescription in men was dyslipidemia [OR = 4.824 (1.442-22.246), p = 0.020]. Pulse pressure [OR = 1.036 (1.007-1.068), p = 0.016] constituted an additional risk factor of NIAD prescription among individuals below the age of 30 years. The risk factors of NIAD prescription for people aged 30 to 50 years were length of stay [OR = 1.097 (1.014-1.196), p = 0.026] and initial blood glucose [OR = 1.078 (1.007-1.168), p = 0.047]. In the case of individuals aged above 50 years, physicians exhibited a higher tendency to prescribe supplementary non-insulin medications to men [OR = 9.385 (1.501-87.789), p = 0.029].Conclusions We identified notable factors that influence discharge prescriptions in patients with T1D. In order to enhance the treatment outcome for the patient, clinicians ought to have a special focus on these indicators or factors.
引用
收藏
页数:13
相关论文
共 51 条
[1]   Adipose tissue and insulin resistance in obese [J].
Ahmed, Bulbul ;
Sultana, Rifat ;
Greene, Michael W. .
BIOMEDICINE & PHARMACOTHERAPY, 2021, 137
[2]   Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial [J].
Ahren, Bo ;
Hirsch, Irl B. ;
Pieber, Thomas R. ;
Mathieu, Chantal ;
Gomez-Peralta, Fernando ;
Hansen, Troels Krarup ;
Philotheou, Areti ;
Birch, Sune ;
Christiansen, Erik ;
Jensen, Thomas Jon ;
Buse, John B. .
DIABETES CARE, 2016, 39 (10) :1693-1701
[3]   Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history [J].
Avogaro, Angelo ;
de Kreutzenberg, Saula Vigili ;
Morieri, Mario Luca ;
Fadini, Gian Paolo ;
Del Prato, Stefano .
LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (12) :882-889
[4]   Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention [J].
Awoniyi, Omodele ;
Rehman, Rabia ;
Dagogo-Jack, Samuel .
CURRENT DIABETES REPORTS, 2013, 13 (05) :669-678
[5]   Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study [J].
Buse, John B. ;
Garg, Satish K. ;
Rosenstock, Julio ;
Bailey, Timothy S. ;
Banks, Phillip ;
Bode, Bruce W. ;
Danne, Thomas ;
Kushner, Jake A. ;
Lane, Wendy S. ;
Lapuerta, Pablo ;
McGuire, Darren K. ;
Peters, Anne L. ;
Reed, John ;
Sawhney, Sangeeta ;
Strumph, Paul .
DIABETES CARE, 2018, 41 (09) :1970-1980
[6]  
[中华医学会糖尿病学分会 Chinese Diabetes Society], 2022, [中华糖尿病杂志, Chinese Journal of Diabetes Mellitus], V14, P1143
[7]   Smoking Cessation, Weight Change, and Risk of Cardiovascular Disease Reply [J].
Clair, Carole ;
Rigotti, Nancy A. ;
Meigs, James B. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (03) :323-323
[8]   Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians - Analysis of the impact of gender, body fat, physical fitness, and life-style factors [J].
Clausen, JO ;
BorchJohnsen, K ;
Ibsen, H ;
Bergman, RN ;
Hougaard, P ;
Winther, K ;
Pedersen, O .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (05) :1195-1209
[9]   Temporal patterns in overweight and obesity in Type 1 diabetes [J].
Conway, B. ;
Miller, R. G. ;
Costacou, T. ;
Fried, L. ;
Kelsey, S. ;
Evans, R. W. ;
Orchard, T. J. .
DIABETIC MEDICINE, 2010, 27 (04) :398-404
[10]   Type 1 diabetes [J].
Daneman, D .
LANCET, 2006, 367 (9513) :847-858